Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Management of Symptomatic Candida krusei Urinary Tract Infection

Initial Assessment and Risk Stratification

  • Evaluate for urinary symptoms (dysuria, frequency, urgency, flank pain, fever) and identify high‑risk features such as neutropenia, very low birth weight (<1500 g), or planned urologic procedures; presence of an indwelling catheter or urinary obstruction also mandates treatment. 1

First‑Line Systemic Therapy (Cystitis and Pyelonephritis)

  • Amphotericin B deoxycholate 0.3–0.6 mg/kg IV once daily for 1–7 days is the recommended initial regimen for both lower (cystitis) and upper (pyelonephritis) C. krusei UTIs; removal of any indwelling bladder catheter is mandatory. 1

Cystitis‑Specific Recommendations

  • Catheter removal must be performed immediately when present to prevent treatment failure and recurrence. 1
  • Alternative bladder irrigation (when systemic therapy is contraindicated and infection is confined to the bladder): amphotericin B 50 mg/L sterile water instilled daily for 5 days; this approach has a high recurrence rate and should be combined with endoscopic removal of obstructing lesions. 2

Pyelonephritis‑Specific Recommendations

  • In addition to systemic amphotericin B, eliminate any urinary tract obstruction (e.g., hydronephrosis) via surgical consultation, and replace or remove nephrostomy tubes/stents when feasible. 3
  • Nephrostomy tube irrigation (if tubes are present): amphotericin B 25–50 mg diluted in 200–500 mL sterile water flushed through the tube. 3

Antifungal Selection Rationale

  • C. krusei exhibits intrinsic resistance to fluconazole, making fluconazole ineffective for this organism. 2
  • Echinocandins (caspofungin, micafungin, anidulafungin) achieve minimal urinary concentrations and are therefore not recommended for urinary tract infections. 2
  • Lipid formulations of amphotericin B (liposomal, amphotericin B lipid complex) do not attain adequate urine levels and should be avoided for UTIs. 2

Dosing Adjustments and Renal Safety

  • Amphotericin B deoxycholate requires no dose reduction in renal impairment; however, it is nephrotoxic, so baseline renal function should be obtained and monitored every 2–3 days, with electrolytes (K⁺, Mg²⁺) checked at least twice weekly. [2][3]
  • Pre‑hydration with normal saline is recommended to mitigate nephrotoxicity. 3
  • Flucytosine, if used, needs significant dose reduction in renal impairment, is not suitable as monotherapy due to rapid resistance, and has poor activity against C. krusei. [3][2]

Monitoring During Therapy

  • Renal panel (serum creatinine, BUN, potassium, magnesium) at least twice weekly while on amphotericin B. 3
  • Complete blood count weekly because amphotericin B can cause anemia. 2

Treatment Endpoints and Duration

  • Therapy should continue until symptoms resolve (fever, dysuria, flank pain) and urine cultures become negative; then a total of 2 weeks of therapy is recommended for both cystitis and pyelonephritis. 1

Critical Pitfalls to Avoid

  • Do not use fluconazole for C. krusei UTIs because of intrinsic resistance. 2
  • Do not use echinocandins for UTIs due to inadequate urinary concentrations. 2
  • Do not use lipid amphotericin formulations for UTIs for the same reason. 2
  • Do not continue therapy without removing indwelling catheters; failure to do so is linked to treatment failure and recurrence. 1
  • Do not treat asymptomatic candiduria unless high‑risk features are present; routine treatment does not improve outcomes. 1

Management of Obstructive Fungus Balls

  • Surgical or endoscopic removal of fungus balls is mandatory; antifungal therapy alone is insufficient. 2
  • Combine surgical intervention with systemic amphotericin B as outlined above. 3
  • If nephrostomy tubes are placed, irrigate with amphotericin B as described for tube irrigation. 3

Treatment of Candida krusei Urinary Tract Infections

Assessment and Initial Management

  • The Infectious Diseases Society of America recommends determining if Candida krusei in urine culture represents true infection requiring treatment or asymptomatic candiduria, especially in high-risk groups such as neutropenic patients, very low birth-weight infants, and patients undergoing urologic manipulation 4, 5
  • Treatment is not recommended for asymptomatic candiduria unless the patient belongs to a high-risk group for dissemination, as stated by the Infectious Diseases Society of America 5, 6
  • Given the patient's advanced age and leukocytosis, treatment is likely warranted as these factors suggest potential for systemic spread, according to the Infectious Diseases Society of America 4, 5

Treatment Algorithm for C. krusei UTI

  • The Infectious Diseases Society of America strongly recommends removing indwelling bladder catheter if present to prevent further infection 4, 5
  • Eliminating any urinary tract obstruction if present is also recommended by the Infectious Diseases Society of America 5, 7
  • First-line treatment for C. krusei urinary tract infection is Amphotericin B deoxycholate, 0.3-0.6 mg/kg daily for 1-7 days, as recommended by the Infectious Diseases Society of America 4, 5, 7
  • Alternative option is AmB deoxycholate bladder irrigation, 50 mg/L sterile water daily for 5 days (for cystitis), according to the Infectious Diseases Society of America 5, 7

Monitoring and Follow-up

  • The Infectious Diseases Society of America recommends repeat urine cultures to document clearance of infection 5, 7
  • For cystitis, treatment should last for 2 weeks, as stated by the Infectious Diseases Society of America 4, 5
  • For pyelonephritis, treatment should last for 2 weeks and ensure resolution of symptoms and negative cultures, according to the Infectious Diseases Society of America 5, 7

REFERENCES

← Return to Home